Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T68039
(Former ID: TTDI01581)
|
|||||
| Target Name |
Cell adhesion molecule (CADM)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Psoriasis [ICD-11: EA90] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | PRX003 | Drug Info | Phase 1 | Psoriasis vulgaris | [1] | |
| Discontinued Drug(s) | [+] 7 Discontinued Drugs | + | ||||
| 1 | ABX-MA1 | Drug Info | Discontinued in Phase 1 | Melanoma | [2] | |
| 2 | ABS-205 | Drug Info | Terminated | Neurodegenerative disorder | [3] | |
| 3 | CY-1748 | Drug Info | Terminated | Deep vein thrombosis | [4] | |
| 4 | GM-7050 | Drug Info | Terminated | Inflammation | [5] | |
| 5 | ICM-3 | Drug Info | Terminated | Graft-versus-host disease | [6] | |
| 6 | NPC-17923 | Drug Info | Terminated | Rheumatoid arthritis | [7] | |
| 7 | Rovelizumab | Drug Info | Terminated | Cerebrovascular disease | [8] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | PRX003 | Drug Info | [1] | |||
| Modulator | [+] 4 Modulator drugs | + | ||||
| 1 | ABS-205 | Drug Info | [10] | |||
| 2 | CY-1748 | Drug Info | [11] | |||
| 3 | GM-7050 | Drug Info | [12] | |||
| 4 | NPC-17923 | Drug Info | [14] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016814) | |||||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009968) | |||||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005714) | |||||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005329) | |||||
| REF 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007018) | |||||
| REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002734) | |||||
| REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006028) | |||||
| REF 9 | Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 1;62(17):5106-14. | |||||
| REF 10 | Drug Discovery and Development for Alzheimer's Disease, 2000. Page(21). | |||||
| REF 11 | US patent application no. 6,492,332, Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation. | |||||
| REF 12 | US patent application no. 6,673,908, Tumor necrosis factor receptor 2. | |||||
| REF 13 | Anti-tumor activity of an ICAM-3 antibody (ICM3) Against human leukemic xenograft tumors in nude mice. Volume 28, Issue 7, Supplement 1, 1 July 2000, Pages 59-60. | |||||
| REF 14 | Inhibition of platelet-activating factor-induced leukocyte adhesion in vivo by a leumedin. Eur J Pharmacol. 1993 Mar 2;232(2-3):169-72. | |||||
| REF 15 | Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.